XERS
Xeris BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
XERS vs peer average
69/100
XERS vs. peer average (B vs. C)
Grade spread
A 1 · B 2 · C 4 · D 2 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
MNKD is the first available peer comparator.
Closest operating peer in the packet: a small-cap commercial biopharma with marketed endocrinology exposure and ongoing commercialization demands, though MannKind's product mix and profitability profile still differ from Xeris.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
XERS
Xeris Biopharma
MNKD
MannKind
Grade
B
B
Momentum
87
65
Value
60
61
Sentiment
37
54
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs MNKD
XERS / MNKD
Grade Position
In line
XERS vs. peer average (B vs. C)
69/100
Momentum
87
XERSValue
60
MNKDSentiment
37
MNKDRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs XERS
MNKD is the first peer returned for this comparison set.